Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | AVPR1A | P37288 | 11/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.34 |
| ▸ | PTAFR | P25105 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30202120 | 0.85 | TDP1 (0.34) | AVPR1AKCNH2PTAFRGABRA1GABRA5 | |
| SCHEMBL23927131 | 0.85 | TDP1 (0.34) | AVPR1AKCNH2PTAFRGABRA1GABRA5 | |
| SCHEMBL23927221 | 0.81 | PTAFR (0.35) | SMN1; SMN2HPGDALDH1A1LMNAAVPR1A | |
| SCHEMBL23927223 | 0.81 | PTAFR (0.35) | SMN1; SMN2HPGDALDH1A1LMNAAVPR1A | |
| SCHEMBL30201891 | 0.80 | AVPR1A (0.35) | AVPR1AKCNH2PTAFRGABRA1GABRA5 | |
| SCHEMBL23927129 | 0.80 | AVPR1A (0.35) | AVPR1AKCNH2PTAFRGABRA1GABRA5 | |
| SCHEMBL30202086 | 0.79 | SMN1; SMN2 (0.38) | SMN1; SMN2HPGDALDH1A1LMNAAVPR1A | |
| SCHEMBL23927195 | 0.79 | SMN1; SMN2 (0.38) | SMN1; SMN2HPGDALDH1A1LMNAAVPR1A | |
| SCHEMBL23927168 | 0.79 | APLNR (0.42) | SMN1; SMN2HPGDALDH1A1LMNAPTAFR | |
| SCHEMBL30202174 | 0.79 | APLNR (0.42) | SMN1; SMN2HPGDALDH1A1LMNAPTAFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4139310-B1 | BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | HOFFMANN LA ROCHE (CH) | 2024-03-27 | — | — | EP | claimed |
| US-20230141603-A1 | BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | claimed |
| EP-4139310-A1 | BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | F. Hoffmann-La Roche AG (CH) | 2023-03-01 | — | — | EP | claimed |
| CN-115667262-A | Benzodiazepine derivatives as GABAA γ 1PAM | 豪夫迈·罗氏有限公司 | 2023-01-31 | — | — | CN | claimed |
| EP-3901155-A1 | NEW BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | F. Hoffmann-La Roche AG (CH) | 2021-10-27 | — | — | EP | claimed |
| EP-4139310-B1 | BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | HOFFMANN LA ROCHE (CH) | 2024-03-27 | — | — | EP | disclosed |
| US-20230141603-A1 | BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230141603-A1 | BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230141603-A1 | BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| EP-4139310-A1 | BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | F. Hoffmann-La Roche AG (CH) | 2023-03-01 | — | — | EP | disclosed |
| WO-2021213952-A1 | BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | F. HOFFMANN-LA ROCHE AG (CH) | 2021-10-28 | — | — | WO | disclosed |
| WO-2021213952-A1 | BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | F. HOFFMANN-LA ROCHE AG (CH) | 2021-10-28 | — | — | WO | disclosed |
| EP-3901155-A1 | NEW BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | F. Hoffmann-La Roche AG (CH) | 2021-10-27 | — | — | EP | disclosed |
| EP-3901155-A1 | NEW BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | F. Hoffmann-La Roche AG (CH) | 2021-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230141603-A1 | BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | GABRA1, GABRB1, GABRB3 | SMN1; SMN2 1264/4885HPGD 2405/4885ALDH1A1 600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.